BRD2 and diabetes mellitus: In this study, NAT was validated as a urinary metabolite marker of hyperacetatemia in three experimental mouse models, including direct dosing through triacetate, indirect input through ethanol metabolism, and endogenous production under diabetes (Figure 5).